Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.73 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142543 | 1.00 | ADAMTS5 (0.80) | ADAMTS5AKR1B1PTPN1PTPN2 | |
| SCHEMBL21326681 | 0.95 | ADAMTS5 (0.82) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5218728 | 0.92 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5218721 | 0.92 | ADAMTS5 (0.89) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL245003 | 0.89 | ADAMTS5 (1.00) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL186520 | 0.89 | ADAMTS5 (1.00) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5218688 | 0.88 | ADAMTS5 (0.82) | ADAMTS5 | |
| SCHEMBL5218697 | 0.88 | ADAMTS5 (0.82) | ADAMTS5 | |
| SCHEMBL5219686 | 0.87 | ADAMTS5 (0.84) | ADAMTS5AKR1B1PTPN1 | |
| SCHEMBL5219681 | 0.87 | ADAMTS5 (0.84) | ADAMTS5AKR1B1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | ADAMTS5 2515/4885AKR1B1 281/4885PTPN1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.